Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 21.28
ZGNX's Cash to Debt is ranked higher than
84% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. ZGNX: 21.28 )
ZGNX' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 21.28

Equity to Asset 0.54
ZGNX's Equity to Asset is ranked higher than
64% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ZGNX: 0.54 )
ZGNX' s 10-Year Equity to Asset Range
Min: -3.87   Max: 0.54
Current: 0.54

-3.87
0.54
F-Score: 5
Z-Score: -1.81
M-Score: 0.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -21.07
ZGNX's Operating margin (%) is ranked higher than
55% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.41 vs. ZGNX: -21.07 )
ZGNX' s 10-Year Operating margin (%) Range
Min: -299.29   Max: -107
Current: -21.07

-299.29
-107
Net-margin (%) -18.31
ZGNX's Net-margin (%) is ranked higher than
54% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.06 vs. ZGNX: -18.31 )
ZGNX' s 10-Year Net-margin (%) Range
Min: -313.81   Max: -106.9
Current: -18.31

-313.81
-106.9
ROE (%) -24.50
ZGNX's ROE (%) is ranked higher than
55% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. ZGNX: -24.50 )
ZGNX' s 10-Year ROE (%) Range
Min: -491.54   Max: -398.45
Current: -24.5

-491.54
-398.45
ROA (%) -6.41
ZGNX's ROA (%) is ranked higher than
58% of the 911 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.14 vs. ZGNX: -6.41 )
ZGNX' s 10-Year ROA (%) Range
Min: -89.81   Max: -52.27
Current: -6.41

-89.81
-52.27
ROC (Joel Greenblatt) (%) -61.84
ZGNX's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 905 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.06 vs. ZGNX: -61.84 )
ZGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -509.09   Max: -336.98
Current: -61.84

-509.09
-336.98
Revenue Growth (3Y)(%) -62.30
ZGNX's Revenue Growth (3Y)(%) is ranked lower than
51% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ZGNX: -62.30 )
ZGNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -62.3
Current: -62.3

EBITDA Growth (3Y)(%) -64.40
ZGNX's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. ZGNX: -64.40 )
ZGNX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -64.4
Current: -64.4

EPS Growth (3Y)(%) -65.20
ZGNX's EPS Growth (3Y)(%) is ranked higher than
51% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. ZGNX: -65.20 )
ZGNX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -65.2
Current: -65.2

» ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ZGNX Guru Trades in Q4 2013

Paul Tudor Jones 41,754 sh (New)
Steven Cohen 21,792 sh (New)
Chuck Royce 1,266,078 sh (-13.64%)
» More
Q1 2014

ZGNX Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce 734,478 sh (-41.99%)
» More
Q2 2014

ZGNX Guru Trades in Q2 2014

Chuck Royce 734,478 sh (unchged)
» More
Q3 2014

ZGNX Guru Trades in Q3 2014

Jim Simons 501,280 sh (New)
Chuck Royce 734,478 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.10
ZGNX's P/B is ranked higher than
74% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. ZGNX: 3.10 )
ZGNX' s 10-Year P/B Range
Min: 2.5   Max: 202
Current: 3.1

2.5
202
P/S 4.80
ZGNX's P/S is ranked higher than
68% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.93 vs. ZGNX: 4.80 )
ZGNX' s 10-Year P/S Range
Min: 0.33   Max: 15.16
Current: 4.8

0.33
15.16
EV-to-EBIT -19.11
ZGNX's EV-to-EBIT is ranked lower than
55% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.99 vs. ZGNX: -19.11 )
ZGNX' s 10-Year EV-to-EBIT Range
Min: -19.7   Max: 113.5
Current: -19.11

-19.7
113.5
Current Ratio 2.30
ZGNX's Current Ratio is ranked higher than
70% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. ZGNX: 2.30 )
ZGNX' s 10-Year Current Ratio Range
Min: 0.85   Max: 3.24
Current: 2.3

0.85
3.24
Quick Ratio 1.81
ZGNX's Quick Ratio is ranked higher than
71% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ZGNX: 1.81 )
ZGNX' s 10-Year Quick Ratio Range
Min: 0.32   Max: 2.54
Current: 1.81

0.32
2.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 125.00
ZGNX's Price/Net Cash is ranked higher than
83% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ZGNX: 125.00 )
ZGNX' s 10-Year Price/Net Cash Range
Min: 16.83   Max: 119
Current: 125

16.83
119
Price/Net Current Asset Value 11.37
ZGNX's Price/Net Current Asset Value is ranked higher than
86% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ZGNX: 11.37 )
ZGNX' s 10-Year Price/Net Current Asset Value Range
Min: 10.1   Max: 10.82
Current: 11.37

10.1
10.82
Price/Tangible Book 3.05
ZGNX's Price/Tangible Book is ranked higher than
79% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.13 vs. ZGNX: 3.05 )
ZGNX' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 142.25
Current: 3.05

2.9
142.25
Price/Median PS Value 1.23
ZGNX's Price/Median PS Value is ranked higher than
71% of the 950 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. ZGNX: 1.23 )
ZGNX' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 2.82
Current: 1.23

0.13
2.82
Earnings Yield (Greenblatt) -5.20
ZGNX's Earnings Yield (Greenblatt) is ranked higher than
56% of the 905 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ZGNX: -5.20 )
ZGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 2.4
Current: -5.2

0.9
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:Z08.Germany,
Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's strategy is to commercialize and develop differentiated central nervous system and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company completed Phase 3 development of Zohydro ER in 2011, and submitted an NDA for Zohydro ER to the FDA in May 2012. The FDA approved the NDA for Zohydro ER in October 2013 and the Company launched the product on March 3, 2014. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
comment on ZGNX Mar 23 2013 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
ZOGENIX, INC. Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits Dec 23 2014
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the... Dec 01 2014
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the... Dec 01 2014
FDA approves Purdue's painkiller that can reduce abuse Nov 20 2014
ZOGENIX, INC. Financials Nov 18 2014
ZOGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 18 2014
Zogenix to Participate in Stifel 2014 Healthcare Conference Nov 12 2014
Zogenix to Participate in Stifel 2014 Healthcare Conference Nov 12 2014
10-Q for Zogenix, Inc. Nov 08 2014
Zogenix beats Street 3Q forecasts Nov 06 2014
Zogenix beats Street 3Q forecasts Nov 06 2014
Zogenix Inc Earnings Call scheduled for 4:30 pm ET today Nov 06 2014
Zogenix Reports Third Quarter 2014 Financial Results Nov 06 2014
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
Zogenix Reports Third Quarter 2014 Financial Results Nov 06 2014
Q3 2014 Zogenix Inc Earnings Release - After Market Close Nov 06 2014
ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Oct 31 2014
Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release... Oct 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK